The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy

Rudolf A. Werner, Seval Beykan, Takahiro Higuchi, Katharina Lückerath, Alexander Weich, Michael Scheurlen, Christina Bluemel, Ken Herrmann, Andreas K. Buck, Michael Lassmann, Constantin Lapa, Heribert Hänscheid

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99mTc-mercaptoacetyltriglycine (99mTc- MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m2 before PRRT (baseline) and 221 ± 45 ml/min/1.73 m2 after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p < 0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatininederived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.

Original languageEnglish
Pages (from-to)41233-41241
Number of pages9
JournalOncotarget
Volume7
Issue number27
DOIs
Publication statusPublished - Jun 1 2016
Externally publishedYes

Fingerprint

Technetium Tc 99m Mertiatide
Octreotide
Peptide Receptors
Radioisotopes
Therapeutics
Kidney
Neuroendocrine Tumors
Glomerular Filtration Rate
Creatinine

Keywords

  • Lu
  • MAG3
  • Neuroendocrine tumor
  • PRRT
  • Renal scintigraphy

ASJC Scopus subject areas

  • Oncology

Cite this

Werner, R. A., Beykan, S., Higuchi, T., Lückerath, K., Weich, A., Scheurlen, M., ... Hänscheid, H. (2016). The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget, 7(27), 41233-41241. https://doi.org/10.18632/oncotarget.9775

The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. / Werner, Rudolf A.; Beykan, Seval; Higuchi, Takahiro; Lückerath, Katharina; Weich, Alexander; Scheurlen, Michael; Bluemel, Christina; Herrmann, Ken; Buck, Andreas K.; Lassmann, Michael; Lapa, Constantin; Hänscheid, Heribert.

In: Oncotarget, Vol. 7, No. 27, 01.06.2016, p. 41233-41241.

Research output: Contribution to journalArticle

Werner, RA, Beykan, S, Higuchi, T, Lückerath, K, Weich, A, Scheurlen, M, Bluemel, C, Herrmann, K, Buck, AK, Lassmann, M, Lapa, C & Hänscheid, H 2016, 'The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy', Oncotarget, vol. 7, no. 27, pp. 41233-41241. https://doi.org/10.18632/oncotarget.9775
Werner, Rudolf A. ; Beykan, Seval ; Higuchi, Takahiro ; Lückerath, Katharina ; Weich, Alexander ; Scheurlen, Michael ; Bluemel, Christina ; Herrmann, Ken ; Buck, Andreas K. ; Lassmann, Michael ; Lapa, Constantin ; Hänscheid, Heribert. / The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. In: Oncotarget. 2016 ; Vol. 7, No. 27. pp. 41233-41241.
@article{b772eef26ddc44258c62d26e97becb54,
title = "The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy",
abstract = "Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99mTc-mercaptoacetyltriglycine (99mTc- MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m2 before PRRT (baseline) and 221 ± 45 ml/min/1.73 m2 after a median follow-up of 370 days. The age-corrected decrease (mean: -3{\%}, range: -27{\%} to +19{\%}) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p < 0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatininederived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.",
keywords = "Lu, MAG3, Neuroendocrine tumor, PRRT, Renal scintigraphy",
author = "Werner, {Rudolf A.} and Seval Beykan and Takahiro Higuchi and Katharina L{\"u}ckerath and Alexander Weich and Michael Scheurlen and Christina Bluemel and Ken Herrmann and Buck, {Andreas K.} and Michael Lassmann and Constantin Lapa and Heribert H{\"a}nscheid",
year = "2016",
month = "6",
day = "1",
doi = "10.18632/oncotarget.9775",
language = "English",
volume = "7",
pages = "41233--41241",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy

AU - Werner, Rudolf A.

AU - Beykan, Seval

AU - Higuchi, Takahiro

AU - Lückerath, Katharina

AU - Weich, Alexander

AU - Scheurlen, Michael

AU - Bluemel, Christina

AU - Herrmann, Ken

AU - Buck, Andreas K.

AU - Lassmann, Michael

AU - Lapa, Constantin

AU - Hänscheid, Heribert

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99mTc-mercaptoacetyltriglycine (99mTc- MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m2 before PRRT (baseline) and 221 ± 45 ml/min/1.73 m2 after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p < 0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatininederived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.

AB - Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99mTc-mercaptoacetyltriglycine (99mTc- MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m2 before PRRT (baseline) and 221 ± 45 ml/min/1.73 m2 after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p < 0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatininederived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.

KW - Lu

KW - MAG3

KW - Neuroendocrine tumor

KW - PRRT

KW - Renal scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=85010829722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010829722&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9775

DO - 10.18632/oncotarget.9775

M3 - Article

C2 - 27259246

AN - SCOPUS:85010829722

VL - 7

SP - 41233

EP - 41241

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -